A 26-week Treatment Randomized, Double-blind, Double Dummy Study to Assess the Efficacy and Safety of QVA149
Status:
Completed
Trial end date:
2014-02-01
Target enrollment:
Participant gender:
Summary
To demonstrate the non-inferiority of QVA149 110/50 µg o.d. to fluticasone/salmeterol 500/50
µg b.i.d. in terms of trough Forced Expiratory Volume in one second (FEV1) (mean of 23 hours
15 min and 23 hours 45 min post QVA149 dose) following 26 weeks of treatment in patients with
moderate to severe COPD
Phase:
Phase 3
Details
Lead Sponsor:
Novartis Pharmaceuticals
Treatments:
Fluticasone Fluticasone Propionate, Salmeterol Xinafoate Drug Combination Fluticasone-Salmeterol Drug Combination Glycopyrrolate Salmeterol Xinafoate Xhance